Here are 1-3 brief analogies to describe Moderna (MRNA):

• The Tesla of vaccine and mRNA drug development. (Highlights its disruptive, platform-based innovation and rapid development, similar to Tesla's impact on the automotive industry).
• A Pfizer or Merck focused purely on cutting-edge mRNA technology. (Places it within the established pharmaceutical landscape but emphasizes its specialized, revolutionary technological core).

• Spikevax (mRNA-1273): Moderna's COVID-19 vaccine, which has received full approval or emergency use authorization globally.
• RSV Vaccine (mRNA-1345): An investigational vaccine candidate for respiratory syncytial virus, currently in late-stage clinical development and awaiting regulatory approval.
• Influenza Vaccines (e.g., mRNA-1010): A portfolio of investigational mRNA-based vaccines targeting various strains of influenza, with some candidates in late-stage clinical trials.
• CMV Vaccine (mRNA-1647): An investigational vaccine candidate for cytomegalovirus, currently in late-stage clinical trials.

Moderna (MRNA) primarily sells its products, predominantly vaccines, to national governments and supranational organizations directly, rather than to other companies or individuals. Therefore, its major direct customers are governments.

Given that governments are not "companies" in the traditional sense (especially not public companies with symbols), and Moderna does not sell primarily to individuals, the company's customer base does not neatly fit into the two conditional categories provided by the prompt. However, to provide the most relevant information:

Major Direct Customers (Governments):

Based on Moderna's financial disclosures, a significant portion of its revenue has historically come from a limited number of national government contracts. Examples of major direct customers include:

• Government of the United States
• Government of Japan
• Government of Canada

Categories of Ultimate Beneficiaries/Populations Served:

While Moderna does not sell directly to individuals, the governments procuring Moderna's vaccines distribute them to their populations. In the context of identifying who ultimately benefits from the company's products, these categories represent the beneficiaries served by the government's procurement and distribution efforts:

• General Adult Population: Individuals typically aged 18 and older, based on vaccine authorization and public health campaigns.
• Vulnerable and High-Risk Groups: Including the elderly, immunocompromised individuals, and those with underlying health conditions, who are often prioritized for vaccination campaigns.
• Pediatric and Adolescent Populations: Specific age cohorts (e.g., 6 months to 11 years, 12-17 years) depending on vaccine approvals and public health recommendations for younger age groups.

• Lonza Group AG (Symbol: LONN)
• Catalent, Inc. (Symbol: CTLT)
• Evonik Industries AG (Symbol: EVK)
• Croda International Plc (Symbol: CRDA)
• Thermo Fisher Scientific Inc. (Symbol: TMO)

Stéphane Bancel, Chief Executive Officer

Stéphane Bancel is the Chief Executive Officer and co-founder of Moderna. Before joining Moderna, he served as the CEO of bioMérieux SA, a French diagnostics company, where he was credited with improving the company's margins. He also held various leadership roles at Eli Lilly and Company, including Managing Director of Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain. Mr. Bancel is a venture partner at Flagship Pioneering, a life-sciences venture capital firm that invests in and incubates companies, with Moderna being one of its portfolio companies. He has also served on the boards of other companies like Indigo Agriculture and Qiagen.

Jamey Mock, Chief Financial Officer

Jamey Mock serves as the Chief Financial Officer of Moderna, overseeing financial, business development, and business services functions. He joined Moderna in September 2022 from PerkinElmer, Inc., a life sciences, diagnostics, and analytical solutions company, where he served as Senior Vice President and CFO since May 2018. During his tenure at PerkinElmer, he oversaw several acquisitions, including a roughly $5.3 billion takeover of BioLegend. PerkinElmer also announced plans to divest its food and enterprise services division to a private equity firm during his time there. Prior to PerkinElmer, Mr. Mock spent nearly two decades in various financial oversight roles at General Electric Company, both in the United States and internationally.

Stephen Hoge, M.D., President

Stephen Hoge was appointed President of Moderna in 2015 and leads all scientific research and clinical development efforts. He joined Moderna in late 2012 as Senior Vice President of Corporate Development. Before his time at Moderna, Dr. Hoge was a partner in the healthcare practice at McKinsey & Company. He previously worked as an emergency room physician in New York City. Dr. Hoge also serves on the Board of Directors of Axcella Health, Inc., which is a private biotechnology company.

Arpa Garay, Chief Commercial Officer

Arpa Garay joined Moderna in May 2022 as the Chief Commercial Officer. In this role, she is responsible for the company's global marketing for pipeline and approved products, and long-term portfolio management. Prior to Moderna, Ms. Garay spent over 15 years at Merck & Co., Inc. Most recently, she served as Chief Commercial Marketing Officer of Human Health at Merck, a position she obtained in February 2022.

Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer

Jerh Collins serves as Moderna's Chief Technical Operations and Quality Officer, overseeing the technical creation, quality, and supply of the company's preclinical, clinical, and commercial programs. He has nearly 30 years of experience in pharmaceutical production and manufacturing, largely gained during his time at Novartis. Before joining Moderna, Dr. Collins was the Head of Global Chemical Operations and Anti-Infectives at Novartis.

The primary emerging threat for Moderna (MRNA) is the significant and ongoing decline in global demand for its COVID-19 vaccine (Spikevax), which has been its sole commercial product and overwhelmingly dominant revenue source. As the pandemic shifts to an endemic phase, initial vaccination campaigns have largely concluded, and demand for boosters is substantially lower than peak levels. This decline is directly impacting Moderna's revenue generation and future growth projections.

A related emerging threat is the rapidly intensifying competition within the mRNA vaccine and therapeutic space. While Moderna was an early leader, established pharmaceutical giants and other biotechnology companies (e.g., Pfizer/BioNTech, GSK, Sanofi) are aggressively developing their own mRNA platforms and pipelines for various infectious diseases (such as influenza and RSV) and other therapeutic areas. This escalating competition could lead to increased price pressure, market share erosion, and challenges for Moderna to establish leadership in new product categories beyond COVID-19, particularly as competitors bring differentiated or potentially superior products to market.

Moderna (MRNA) focuses on messenger RNA (mRNA) therapeutics, primarily mRNA vaccines and therapies. The addressable markets for their main products and services vary by product and region.

Moderna's Main Products and Addressable Markets:

• COVID-19 Vaccine (Spikevax, mNEXSPIKE)
  • U.S. Private Market: The potential annual private market in the U.S. for COVID-19 vaccines could be approximately $12.9 billion, assuming half of the U.S. adult population receives an annual booster at a price of $100 per dose. Other scenarios estimate the U.S. private market at $10.6 billion (at $82/shot) or $8.3 billion (at $64/shot).
  • Global Market: The global COVID-19 vaccine market was valued at US$92.6 billion in 2021 and is projected to reach over US$9.9 billion by the end of 2031, with a compound annual growth rate (CAGR) of -13.6% from 2022 to 2031. More recently, the global COVID-19 vaccine market is expected to reach USD 13.71 billion in 2025 and decline to USD 8.28 billion by 2030, reflecting a CAGR of -9.10%.
• RSV Vaccine (mRESVIA)
  • U.S. Market: Moderna's mRESVIA has received expanded FDA approval to include at-risk adults aged 18-59, tapping into an estimated 45 million at-risk individuals in the U.S. Analyst projections suggest mRESVIA could achieve peak sales of $8 billion to $10 billion by 2029. Moderna's sales for its RSV vaccine in Q3 2025 were $2 million. Some estimates indicate peak RSV vaccine sales for Moderna around $2.5 billion.
  • Global Market: The global RSV vaccines market size was valued at USD 1.60 billion in 2024 and is projected to grow from USD 1.05 billion in 2025 to USD 2.49 billion by 2032, exhibiting a CAGR of 13.1%. North America held a dominant market share of 82.5% in 2024. Another report values the global RSV vaccine market at $1,472.70 million in 2024, anticipating a reduction to $1,149.41 million in 2025 and $731.05 million by 2040.
• Influenza Vaccine (mRNA Flu Vaccine)
  • Global Market: The global mRNA flu vaccine market size was valued at USD 9.43 billion in 2024 and is projected to reach USD 19.20 billion by 2032, with a CAGR of 9.30%. The broader global influenza vaccine market is calculated at USD 8.49 billion in 2024, grew to USD 9.08 billion in 2025, and is projected to reach around USD 16.73 billion by 2034, expanding at a CAGR of 7.02%. North America led the influenza vaccine market with a 53% share in 2024. The flu RNA vaccines market, specifically, was valued at USD 982 million in 2024 and is projected to grow to USD 1.93 billion by 2031, with a CAGR of 10.4%.
• CMV Vaccine (mRNA-1647)
  • Global Market: The global cytomegalovirus (CMV) vaccine market is estimated to be approximately $500 million in 2025 and is projected to grow at a conservative CAGR of 15% from 2025-2033. The global Cytomegalovirus (CMV) Infection Therapeutic Market is estimated to be valued at USD 248.3 million in 2025 and is expected to reach USD 406.6 million by 2032, growing at a CAGR of 7.3%.
• Rare Disease Therapeutics
  • Global Market: The RNA-based Therapies Market, which encompasses rare diseases, was valued at USD 90.56 billion in 2024 and is projected to reach USD 213.54 billion by 2033, expanding at a CAGR of 10.0%. Rare genetic diseases contributed US$22 billion to this market in 2024. Moderna is developing mRNA therapies for rare genetic disorders like propionic acidemia (PA) and methylmalonic acidemia (MMA), which affect fewer than 200,000 people globally. There are approximately 7,000 rare diseases affecting over 300 million people worldwide, but only about 5% have approved drugs. The broader mRNA therapeutics market size was USD 19.68 billion in 2024 and is projected to reach around USD 42.64 billion by 2034.

Here are 3-5 expected drivers of future revenue growth for Moderna (MRNA) over the next 2-3 years:

1. Launch and Growth of New Respiratory Vaccines: Moderna anticipates significant revenue growth from its pipeline of non-COVID-19 respiratory vaccines. Key candidates include its Respiratory Syncytial Virus (RSV) vaccine, mRESVIA, which has received approvals in various regions including the U.S., EU, Norway, Iceland, and Qatar, and is expected to contribute to sales, despite initial lower-than-anticipated uptake. The company's seasonal influenza vaccine (mRNA-1010) and a combination influenza/COVID-19 vaccine (mRNA-1083) are both in Phase 3 clinical trials, with potential regulatory approvals and market launches by 2026. Moderna aims to launch up to 10 new products over the next three years, diversifying its product portfolio beyond its initial COVID-19 vaccine.
2. Advancement and Commercialization of Oncology and Rare Disease Programs: Moderna is actively developing a robust pipeline in oncology and rare diseases, areas poised to become significant long-term revenue drivers. The company has over 40 programs in its non-COVID pipeline, including notable progress in melanoma therapies through a strategic partnership with Merck (mRNA-4157) and rare disease therapies like mRNA-3705 for Methylmalonic acidemia (MMA), with a registrational study expected to begin in 2026. Successful progression and commercialization of these programs, particularly the personalized cancer treatments, could establish new substantial revenue streams.
3. Continued Market Share Gains for Next-Generation COVID-19 Vaccines: While the overall COVID-19 vaccine market is contracting, Moderna continues to focus on its updated and next-generation COVID-19 vaccines, such as mNEXSPIKE and an updated Spikevax formulation. These have received approvals for the 2025-2026 season in several countries and are showing gains in market share, with mNEXSPIKE accounting for a growing portion of Moderna's COVID vaccine sales. The company's efforts in public health campaigns and timely shipments aim to maintain and grow its share in the evolving endemic COVID-19 market.
4. International Expansion and Strategic Partnerships: Moderna is expanding its global footprint and securing multiyear supply agreements with various countries, including Canada, the U.K., and Australia. These strategic partnerships help broaden market access for its current and future mRNA vaccine portfolio, contributing to international sales. The establishment of local manufacturing facilities and regulatory approvals in these regions further supports market penetration and long-term revenue generation.

Share Repurchases

• Moderna initiated a $3 billion share repurchase program in February 2022, which was completed in early Q4 2022.
• An additional $3 billion share repurchase program was authorized in August 2022, with $2.8 billion remaining under this authorization as of February 2023.
• Moderna repurchased $3.3 billion of common stock in 2022. In 2023, the company repurchased $1.153 billion in shares.

Share Issuance

• Moderna's shares issued for Q2 2025 amounted to $14.0 million.
• The annual value of shares issued for fiscal year 2024 was $66.0 million, an increase of 43.48% from the previous year.
• In connection with equity compensation, 7 million shares of common stock were issued between Q3 2021 and Q4 2022.

Inbound Investments

• From 2020 to 2021, Moderna received $955 million from Operation Warp Speed to accelerate the development of its COVID-19 vaccine.
• In 2020, Moderna received $483 million from the Biomedical Advanced Research and Development Authority (BARDA) for vaccine development.
• In March 2023, Moderna and Generation Bio announced a strategic collaboration where Generation Bio received a $40 million upfront cash payment and a $36 million equity investment from Moderna.

Outbound Investments

• Moderna made its first acquisition in 2023, purchasing Japanese DNA manufacturer OriCiro Genomics for $85 million. The acquisition aims to enhance cell-free DNA synthesis and amplification technologies, potentially reducing large-scale manufacturing time by up to 30%.
• In December 2022, Moderna committed to investing in mRNA research and development (R&D) in the UK and building a vaccine manufacturing center with a capacity of up to 250 million vaccines per year, as part of a 10-year partnership with the UK government.
• In 2023, Moderna entered an agreement with the Chinese government to develop mRNA drugs for exclusive use in China.

Capital Expenditures

• Capital expenditures for 2025 are expected to be approximately $0.3 billion.
• Moderna's capital expenditures increased from $55.665 million in 2020 to $1.015 billion in 2024.
• Expected capital expenditures for 2024 were approximately $0.9 billion, and for 2023 they were approximately $1.0 billion. These investments are primarily focused on expanding manufacturing and research facilities.